Ito Kazuto, Kakehi Yoshiyuki, Naito Seiji, Okuyama Akihiko
Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Int J Urol. 2008 Sep;15(9):763-8. doi: 10.1111/j.1442-2042.2008.02125.x.
The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or Western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8 times higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death.
与美国或西欧相比，日本使用前列腺特异性抗原（PSA）筛查前列腺癌的普及率仍然很低。未来前列腺癌的死亡率将会上升，到2020年将比2000年高出2.8倍。因此，迫切需要确定最佳可行对策以降低前列腺癌死亡率。
